{"entity":{"id":"nct04564157","kind":"trial","name":"New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy","aka":["NADIM-ADJUVANT"],"tldr":"A phase 3 trial of carboplatin, paclitaxel / nab-paclitaxel and nivolumab in lung cancer, run by Fundación GECP, active but no longer recruiting.","summary":"New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy is a phase 3, randomised interventional study registered as NCT04564157 by Fundación GECP, with a registry enrolment figure of 210 participants, started 2021-01-13 and due to reach its primary completion in 2030-04-01. Interventions recorded: Carboplatin; Paclitaxel; Nivolumab. Conditions listed: Non-Small Cell Lung Cancer; Adjuvant Chemotherapy. Primary outcome: The disease-free survival. Lung eligibility wording from the registry: \"Patients diagnosed of primary non-small cell lung cancer, histologically confirmed\". Sites: Spain. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04564157","url":"https://clinicaltrials.gov/study/NCT04564157"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","paclitaxel","nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04564157","phase":"3","setting":"A Phase III Clinical Trial of Adjuvant Chemotherapy vs Chemoimmunotherapy for Stage IB-IIIA Completely Resected Non-small Cell Lung Cancer (NSCLC) Patients.","sponsor":"Fundación GECP","enrolled":210,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04564157/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}